Pharvaris (NASDAQ:PHVS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.
Pharvaris Price Performance
Shares of PHVS stock opened at $14.83 on Wednesday. The business has a fifty day moving average of $16.59 and a 200 day moving average of $18.83. Pharvaris has a 1 year low of $14.14 and a 1 year high of $25.50. The firm has a market capitalization of $775.46 million, a price-to-earnings ratio of -5.30 and a beta of -3.02.
Analyst Upgrades and Downgrades
Separately, JMP Securities raised their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.
Pharvaris Company Profile
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
- Five stocks we like better than Pharvaris
- High Flyers: 3 Natural Gas Stocks for March 2022
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- 3 Best Fintech Stocks for a Portfolio Boost
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
